European Commission OKs Lynparza for Metastatic CRPC With BRCA Mutations

European Commission OKs Lynparza for Metastatic CRPC With BRCA Mutations
The European Commission has approved Lynparza (olaparib) to treat people with metastatic castration-resistant prostate cancer (mCRPC) who carry mutations in the DNA repair genes BRCA1 and BRCA2. The approval follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency. "This approval in the EU is a landmark moment that begins a new era of precision medicine in prostate cancer," Johann de Bono, PhD, a professor at The Institute of Cancer Research, London, said in a press release. Damage to a cell's DNA can be fatal, which is why cells have several molecular pathways they can use to detect and repair DNA damage. The BRCA genes are invol
Subscribe or to access all post and page content.